CTLA4 and neoplasm: In particular, immune checkpoint inhibitors targeting PD-1, PD-L1, or CTLA-4 have been found to restore anti-tumor immune responses in some cancer entities, thus leading to profound therapeutic improvements in patients with advanced cancer diseases.